Refractory Hematologic Malignancy
8 clinical trials · Condition
◉ Watch Refractory Hematologic Malignancy
| Record | Firm | Date |
|---|---|---|
| A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. (NCT05205252) | Epizyme, Inc. | 2021-12-22 |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies (NCT04681105) | City of Hope Medical Center | 2020-11-18 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer (NCT03739606) | City of Hope Medical Center | 2020-10-20 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) (NCT03328078) | Curis, Inc. | 2017-12-28 |
Track Refractory Hematologic Malignancy automatically
Every clearance here is in the API, with alerts when new ones post.